PepGen Inc. Common Stock
$2.90
$0.01 (+0.35%)
$2.85Day Range$2.98
Key Statistics
Market Cap
$200.16M
Shares Outstanding
69.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 6, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$2.92
Day High
$2.98
Day Low
$2.85
Volume
613.5K
VWAP
$2.89
Prev Close
$2.89
Transactions
--
Acc. Volume
--
About PepGen Inc. Common Stock
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
PHARMACEUTICAL PREPARATIONSSIC 283457 employees1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210703-456-8000IPO May 6, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001835597
- Composite FIGI
- BBG012232618
- Share Class FIGI
- BBG012232627
- Ticker Root
- PEPG
- SIC Code
- 2834
About PepGen Inc. Common Stock (PEPG) Stock
PepGen Inc. Common Stock (PEPG) closed the 2026-09-16 session at $2.90, up 0.35% versus the previous close (+0.01). The stock opened at $2.92 and traded between $2.85 and $2.98 during that session. Session trading volume was 613K shares. The volume-weighted average price (VWAP) is $2.89.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
PepGen Inc. Common Stock has a market capitalization of $200.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PEPG is listed on the XNAS exchange. The company employs approximately 57 people. PepGen Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2022-05-06.
On this page you can find market PEPG stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.